SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Lupus/Nephritis
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (64)9/14/2005 12:53:00 PM
From: keokalani'nui  Read Replies (1) of 95
 
CYCLACEL ANNOUNCES COLLABORATION
ON NEPHROLOGY APPLICATIONS OF CDK INHIBITORS

Dundee, Scotland, U.K., 14 September 2005 - Cyclacel Group plc ("Cyclacel"), the cell cycle-based biopharmaceutical company, announced today an evaluation and option agreement with enzyme Corporation in the field of renal diseases involving certain of Cyclacel's preclinical stage Cyclin-Dependent inase (CDK) inhibitor molecules.

Under the terms of the agreement Cyclacel granted Genzyme an exclusive option to license two preclinical stage CDK inhibitors for further development in renal diseases and certain related conditions. The agreement does not include any rights in oncology or other therapeutic areas.

The Cyclacel compounds are derived from multiple pharmacophores, act selectively on CDK enzyme targets and possess drug-like properties. Genzyme will conduct a preclinical evaluation of the optioned compounds, including assessing efficacy in relevant disease models. During the option period the parties may pursue a collaboration and license agreement with the objective of development and commercialization of the Cyclacel compounds. Financial terms of the option agreement were not disclosed.

Cyclacel scientists and academic collaborators have demonstrated the beneficial effects of pharmacological CDK inhibition in preclinical models of renal disease including lupus nephritis, crescentic glomerulonephritis, HIV associated nephropathy and IgA nephropathy.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News